Sickle Cell

Key opinion leaders focus on the use of crizanlizumab for painful crisis frequency in sickle cell disease.

While obesity is less common in pediatric sickle cell patients, BMI may impact airway resistance in this population.

Early results from the MOMENTUM study show that treated patients experienced fewer vaso-occlusive episodes and related hospital admissions.

Wally Smith, MD, gives insight on using voxelotor in patients during the COVID-19 pandemic.  

Looking at voxelotor in sickle cell disease, experts review the HOPE study.

The twice-daily oral agent is indicated for patients ≥3 years of age

Patients with multiple hospital visits were more likely to utilize more than one (conventional and/or alternative) pain relief technique.

Abdullah Kutlar, MD, reviews the benefits and risks of treating patients with hemopoietic stem cell transplant.  

Experts discuss the considerations, as well as a specific case in patients receiving hemopoietic stem cell transplant (HSCT).

Insight on the screening and monitoring for red blood cell transfusion for the management of sickle cell disease.

Wally Smith, MD, discusses L-glutamine in the treatment of SCD.

Data also suggests the nonionic block polymer surfactant may be harmful for children <16 years of age.

Elevated B cell activating factor levels in children and adults were associated with the development of FVIII inhibitors, which may lead to FVIII infusion failures.

Patrick McGann, MD, MS, reviews the role of hydroxyurea in sickle cell disease, touching on the mechanism of action and expected outcomes.

Clinicians dive into the impact of sickle cell on quality of life and symptom management

SDOCT imaging shows that sickle cell patients with no clinical evidence of retinopathy have considerably lower central macular thickness when compared with healthy controls.

Compared with controls, children and adolescents with sickle cell anemia were more likely to be underweight and exhibit signs of stunting and wasting.

Patients who received voxelotor 1500 mg achieved significant improvements in markers of hemolysis through week 72 when compared with the placebo group.

Abdullah Kutlar, MD, reviews the guideline recommendations for screening and monitoring of anemia-related sickle cell disease manifestations.

Key opinion leaders give insight on the presentation of sickle cell disease, also highlighting acute vs chronic complications of the disease.

A new study supports the potential association between hydroxyurea and improved neurocognitive performance in pediatric patients.

An interview with a phase 2 investigator on the the novel drug's potential in a field it wasn't originally designed to treat.

New phase 2 data from a 24-week assessment suggest the first-in-class drug could benefit exercise and pulmonary-vascular outcomes.

Experts discuss the prevalence and burden of sickle cell disease.

Wally Smith, MD, and Abdullah Kutlar, MD provide an overview of sickle cell disease and its pathophysiology.